Characterization of lung concentrations of the antibiotics piperacillin/tazobactam and levofloxaci

Phase 1

• Conditions: Pneumonia; Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]

• Registration Number: EUCTR2019-000955-16-AT
• Lead Sponsor: Medical University of Vienna

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-07
• Last Update Posted: 9 September 2024

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

• Written informed consent
• Planned bilateral lung transplantation
• Diagnosis of COPD or CF • Age:>18and<90years
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

• Inability to give informed consent • Known allergy to study drugs
• Prior lung transplantation
• Preoperative renal failure
• Chronic severe renal insufficiency including haemodialysis • Chronic severe liver disease
• ECLS bridging

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified